Skip to main content

Table 1 Characteristic of patients with Behçet’s disease who were enrolled in the study

From: Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan

Characteristics Yokohama City University registry (n = 657) Japan national registry (n = 6754)
Sex: female/male, n (%) 372/285 (56.6/43.4) 3990/2764 (59.1/40.9)
Age of diagnosis (mean ± SD) 36.58 ± 12.29 36.68 ± 14.23
Observation period (mean ± SD) 13.72 ± 11.79 4.14 ± 7.62
Disease phenotype
 Oral ulcer, n (%) 653 (99.4) 6336 (93.8)
 Skin involvement, n (%) 585 (89.0) 5483 (81.2)
 Eye involvement, n (%) 392 (59.7) 2344 (34.7)
 Genital ulcer, n (%) 474 (72.1) 4242 (62.8)
 Arthritis, n (%) 346 (52.7) 3311 (49.0)
 Epididymitis, n/available data number (%) 15/285 (5.3) 257/2764 (9.3)
 Gastrointestinal involvement, n (%) 113 (17.2) 906 (13.4)
 Vascular involvement, n (%) 55 (8.4) 148 (2.2)
 Neurological involvement, n (%) 67 (10.2) 350 (5.2)
 Pathergy test, n/available data number (%) 74/170 (43.5) 1361/4225 (32.2)
Other characteristics
 HLA-B51, n/available data number (%) 214/449 (47.7) 1389/3141 (44.2)
 Fulfilling ISG criteria, n (%) 583 (88.7) 4980 (73.7)
 Fulfilling ITR-ICBD criteria, n (%) 645 (98.2) 5586 (82.7)
 Smoking, n/available data number (%) 233/455 (51.2) N/A
 Hospitalization, n/available data number (%) 239/522 (45.8) 1556/6002 (25.9)
 Blindness, n/available data number (%) 98/582 (16.8) N/A
 Death caused by BD, n/available data number (%) 3/520 (0.6) N/A
Treatments
 Colchicine, n (%) 375/522 (71.8) 2942 (43.6)
 Glucocorticoid, n (%) 236/522 (45.2) 2352 (34.8)
 Maximum Prednisolone dose (mg/day, mean ± SD) 11.75 ± 17.76 N/A
 Methylprednisolone pulse therapy, n/available data number (%) 36/522 (6.9) N/A
 Immunosuppressant therapy, n/available data number (%) 203/522 (38.9) 578 (8.6)
 Biologics, n (%) 95 (14.5) N/A
  Infliximab, n (%) 86 (13.1) N/A
  Adalimumab, n (%) 24 (3.7) N/A
  Others, n (%)* 3 (0.5) N/A
 Time from diagnosis to biologics (years, mean ± SD) 6.22 ± 8.52 N/A
  1. BDRC Behçet’s Disease Research Committee, ISG International Study Group, ITR-ICBD International Team for the Revision of the International Criteria for Behçet’s Disease, N/A not available
  2. *Others: etanercept 2, tocilizumab 1